Genentech Gains Expanded Access to Sangamo's Protein Production Technology
Sangamo BioSciences, Inc. (Richmond, CA) has entered into a second research and license agreement with Genentech, Inc. (South San Francisco, CA), expanding on the original agreement to include additional targets for potential improvement of production cell lines using Sangamo's proprietary zinc finger DNA-binding protein nuclease (ZFN) technology
Sangamo BioSciences, Inc. (Richmond, CA) has entered into a second research and license agreement with Genentech, Inc. (South San Francisco, CA), expanding on the original agreement to include additional targets for potential improvement of production cell lines using Sangamo's proprietary zinc finger DNA-binding protein nuclease (ZFN) technology.
Zinc finger proteins (ZFPs) are the dominant class of naturally occurring transcription factors in organisms from yeast to humans. Transcription factors, which are found in the nucleus of every cell, bind to DNA to regulate gene expression. Though there are many kinds of transcription factors, only ZFPs are amenable to engineering and precise targeting to a particular gene or genes of interest. ZFNs are engineered forms of ZFPs that also contain a nuclease component, which can induce modification of a target gene of interest.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
